A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin.
The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time.
Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 [NCT06671483] or TAK-279-PsA-3002 [NCT06671496]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD).
Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.

Start Date27 Feb 2026

Sponsor / Collaborator

Takeda Pharmaceutical Co., Ltd.

NCT07244263

/ Not yet recruitingPhase 2

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may become swollen and red over time. If they fill with pus, these lumps are called abscesses; these can also burst. Over time, the area can get scars and tunnels on or under the skin. Recent studies suggest that the condition may start when hair follicles become damaged and blocked. This impacts the skin and may activate the body's germ-fighting (immune) system. This allows bacteria to grow on the skin which worsens the condition and can cause abscesses.
The main aims of this study are to learn how safe zasocitinib is, how well it works and how well adults with HS tolerate it compared with a placebo.
The participants will receive the study treatment (either zasocitinib or placebo) for up to 4 months (16 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. After the first 4 months, all participants (also those who initially received placebo) will then receive zasocitinib for up to 8 months (36 weeks).
During the study, participants will visit their study clinic 12 times.

Start Date06 Feb 2026

Sponsor / Collaborator

Takeda Pharmaceutical Co., Ltd.

NCT07250802

/ RecruitingPhase 3

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it.
The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children.
At first, only teenagers who meet the study rules can participate in this study. Children may only start to participate once enough information has been collected from other studies with zasocitinib.
Participants in Part A will initially be assigned to receive either zasocitinib or placebo for the first 16 weeks of treatment, then all participants will receive zasocitinib through the end of the study. All participants in Part B will be assigned to receive treatment with zasocitinib throughout the study.
Participants will be in the study for up to 4 years and 2 months (217 weeks), including up to 35 days for the screening period, 208 weeks of treatment (Part A and Part B) and a 4-week safety follow-up period. During the study, participants will visit their study site multiple times.

Start Date04 Dec 2025

Sponsor / Collaborator

Takeda Pharmaceutical Co., Ltd.

100 Clinical Results associated with Zasocitinib

100 Translational Medicine associated with Zasocitinib

100 Patents (Medical) associated with Zasocitinib

Literatures (Medical) associated with Zasocitinib

01 Oct 2025·ANNALS OF THE RHEUMATIC DISEASES

Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study

Article

Author: Hong, Ting ; Trivedi, Mona ; Zhang, Xinyan ; Kivitz, Alan ; Dokoupilova, Eva ; Srivastava, Bhaskar ; Muensterman, Elena Tomaselli ; Kavanaugh, Arthur ; Weng, Haoling Holly ; van der Heijde, Désirée ; Poirier, Gabrielle ; Valenzuela, Guillermo ; Lertratanakul, Apinya ; Klimiuk, Piotr A ; Baraliakos, Xenofon ; Dasen, Sue ; Pothula, Peter ; Chen, Jingjing

OBJECTIVES:

To assess the efficacy, safety, and tolerability of the investigational, oral, allosteric, highly selective, and potent tyrosine kinase 2 inhibitor zasocitinib (TAK-279) in patients with active psoriatic arthritis (PsA).

METHODS:

In this phase 2b, randomised, multicentre, double-blind, placebo-controlled, multiple-dose study, patients (≥18 years, with PsA symptoms for ≥6 months) received 30 mg, 15 mg, or 5 mg zasocitinib or placebo (1:1:1:1) once daily for 12 weeks, with a 4-week safety follow-up. The primary endpoint was American College of Rheumatology (ACR)20 response at week 12. Secondary efficacy endpoints included ACR50 response, ACR70 response, Psoriasis Area and Severity Index (PASI) 75 response among those with ≥3% body surface area at baseline and minimal disease activity (MDA) at week 12.

RESULTS:

Overall, 290 patients (mean [SD] age, 49.9 [11.6] years; 57.2% female) received treatment. At week 12, 30 mg or 15 mg zasocitinib treatment resulted in significantly higher ACR20 responses (54.2%; P = .002 and 53.3%; P = .002, respectively) than placebo (29.2%). A numerically higher number of ACR50 responses were achieved at week 12 with 30 mg (26.4%; nominal P = .009) or 15 mg (26.7%; nominal P = .005) zasocitinib than placebo (9.7%). In addition, 30 mg zasocitinib demonstrated a numerically higher number of ACR70 responses (13.9% versus 5.6%, respectively; nominal P = .158), PASI 75 responses (45.7% versus 15.4%, respectively; nominal P = .002), and MDA (29.2% versus 12.5%, respectively; nominal P = .014) at week 12 versus placebo. In this small study of limited duration, most adverse events were mild/moderate and were more frequently observed in the higher dose group. In this small sample size, no new safety signals or clear dose-dependent laboratory parameter changes were identified.

CONCLUSIONS:

Here, 30 mg and 15 mg zasocitinib demonstrated efficacy across core domains in patients with active PsA with no new safety signals. These findings will be confirmed in ongoing larger studies of longer duration.

01 Aug 2025·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Identification of small molecule activators targeting TYK2 pseudokinase domain

Article

Author: Taniguchi, Haruka ; Nishioka, Yu ; Sawa, Masaaki ; Kinoshita, Takayoshi ; Matsumoto, Hirokazu ; Hatakeyama, Mariko ; Wang, Tien-Cheng

Tyrosine kinase 2 (TYK2) plays a crucial role in both adaptive and innate immune responses. The catalytic activity of the TYK2 JH1 kinase domain is controlled by the TYK2 JH2 pseudokinase domain and stabilized to maintain its inactive state until the upstream receptor activations. Here, we report the discovery of aminopyridine analogs as novel TYK2 activators through structural modification of a known JH2 binder. Compound 16b demonstrated a dose-dependent increase in TYK2 enzymatic activity.

01 Jan 2026·JOURNAL OF INVESTIGATIVE DERMATOLOGY

Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor

Article

Author: Bunick, Christopher G ; Dunbar, Faith ; McInnes, Iain B ; Kong, Kok-Fai ; Sano, Yasuyo ; Xia, Guliang ; Heap, Graham A ; Halkowycz, Petro ; Wilson, Elizabeth ; Mehrotra, Shailly ; Spector, Taylor ; Durairaj, Chandra

Zasocitinib (TAK-279) is an investigational, oral, highly selective, and potent allosteric TYK2 inhibitor. This study assessed the TYK2 inhibitory selectivity and potency of zasocitinib versus those of licensed TYK2 and Jak inhibitors. Binding affinities were determined using homogenous time-resolved fluorescence. In vitro concentration-percentage inhibition curves for IL-23-phosphorylated signal transducer and activator of transcription (pSTAT)3, type I IFN-pSTAT3, IL-12-pSTAT4, IL-2-pSTAT5, and thrombopoietin-pSTAT3 pathways were established using human whole-blood assays. Relationships between concentration and percentage inhibition were determined to estimate half-maximal inhibitory concentration. Times above half-maximal inhibitory concentration and percentage daily inhibition were modeled from simulated clinical concentrations. Zasocitinib bound the TYK2 Janus homology 2 domain with an inhibitory constant of 0.0087 nM, demonstrating more than 1 millionfold selectivity over Jak1. Zasocitinib potently inhibited TYK2 signaling, with half-maximal inhibitory concentrations of 48.2 nM (95% confidence interval = 36.8-63.1 nM), 21.6 nM (95% confidence interval = 17.3-26.9 nM), and 57.0 nM (95% confidence interval = 44.2-73.4 nM) for IL-23-pSTAT3, type I IFN-pSTAT3, and IL-12-pSTAT4 pathways, respectively; zasocitinib showed no inhibition of Jak1/2/3. Simulated clinical concentrations of 30 mg zasocitinib once daily exceeded the TYK2 half-maximal inhibitory concentration for 24 hours, maintaining >90% daily inhibition, with no Jak1/2/3 inhibition. The distinct potent and selective inhibition profile of zasocitinib defines it as a next-generation TYK2 inhibitor.

News (Medical) associated with Zasocitinib

19 Dec 2025

·www.fiercepharma.com

Fierce Pharma Asia—Daiichi ADCs' 1st-line nod, trial deaths; Takeda's TYK2 trial win

Enhertu's first-line breast cancer approval, unexpected death cases in a Daiichi Sankyo antibody-drug conjugate trial and positive readouts from Takeda's Sotyktu challenger made our news this week. In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for AstraZeneca-partnered Enhertu in first-line HER2-positive breast cancer but paused a phase 3 trial of its Merck & Co.-partnered antibody-drug conjugate due to unexpected patient deaths. Takeda plans to file its TYK2 inhibitor for an FDA approval following a pair of positive phase 3 trials in psoriasis. And more.1. AZ, Daiichi score with FDA nod for Enhertu combo in 1st-line breast cancerThe FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu in combination with Roche’s Perjeta as the first new first-line treatment of HER2-positive metastatic breast cancer in more than a decade. In the Destiny-Breast09 trial, the combo significantly lowered the risk of progression or death by 44% compared with the traditional THP regimen.2. Patient deaths prompt partial hold for Daiichi-Merck’s global phase 3 ADC programDaiichi has paused enrollment in a phase 3 trial of its Merck & Co.-partnered B7-H3 antibody-drug conjugate, ifinatamab deruxtecan, after an unexpected number of deaths from interstitial lung disease. The partial clinical hold comes as the pharma partners said they were aiming for an accelerated approval for the candidate for pretreated small cell lung cancer based on a phase 2 readout.3. Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 successTakeda said its oral TYK2 inhibitor zasocitinib, a potential competitor to Bristol Myers Squibb’s Sotyktu, succeeded in two phase 3 trials in moderate to severe plaque psoriasis. The drug beat placebo on the trials’ co-primary endpoints of static Physician Global Assessment 0/1 and the Psoriasis Area and Severity Index 75 at Week 16. The company plans to file for an FDA approval. 4. Biosecure Act heads to Trump's desk with defense spending bill after Senate voteBoth the House of Representatives and the Senate have passed the annual defense bill that includes the revamped Biosecure Act. President Donald Trump is expected to sign the massive defense package into law. Once enacted, the updated Biosecure Act will raise hurdles for life sciences companies from China.5. Fosun signs up to take on China's Green Valley, revive controversial Alzheimer's medFosun Pharma is spending about $200 million to take a 53% stake in Green Valley Pharmaceuticals, aiming to revive the latter’s controversial Alzheimer’s disease med, sodium oligomannate (GV-971), after Chinese regulators opted not to renew the drug’s conditional approval. The Shanghai Stock Exchange sent Fosun a regulatory letter related to the proposed transaction. Such a letter typically reminds a public company of potential regulatory breaches.6. Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1BBristol Myers Squibb signed on China’s Harbour BioMed to discover multispecific antibodies. Harbour could receive payments totaling $90 million plus development and commercial milestones of up to $1.035 billion. Before BMS, Harbour had forged collaborations with Otsuka and AstraZeneca earlier this year.7. Sanofi signs $1B biobucks pact for Alzheimer's asset in 2nd biotech deal of the daySanofi has signed a licensing deal worth up to $1.04 billion with South Korean biotech Adel. The pact focuses on ADEL-Y01, a tau-targeting antibody for Alzheimer’s disease. Sanofi will pay $80 million upfront for the clinical-stage asset and related backup compounds. Rather than broadly targeting tau, the drug focuses on tau acetylated at lysine-280.Other News of Note: 8. AI drug designer Insilico Medicine aims to generate nearly $300M in Hong Kong IPO9. Keytruda, Padcev keep winning streak with another patient survival benefit in bladder cancer10. Yarrow blooms with $1.37B deal, landing autoimmune thyroid disease drug from China's GenSci11. Yarrow to go public in reverse merger with Vyne (release)12. Boehringer inks AI protein design pact with Korea’s Galux (release)13. Hansoh sells regional rights to EGFR inhibitor to Glenmark in potential $1B deal (release)14. Lilly to help Korea’s Medi&Gene advance an obesity asset (release)

License out/inPhase 3Drug ApprovalADC

19 Dec 2025

·pharma.economictimes.indiatimes.com

Takeda's AI-crafted psoriasis pill succeeds in late-stage studies

REUTERS/Kim Kyung-Hoon/File Photo Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial intelligence, succeeded in two late-stage studies. More than half the plaque psoriasis patients across the studies showed clear or almost clear skin after 16 weeks of treatment with the once-daily drug, zasocitinib, the company said. Takeda plans to file marketing applications with the U.S. Food and Drug Administration and other regulatory authorities in 2026. If approved, zasocitinib would join a crowded plaque psoriasis market featuring well-established oral rivals like Bristol Myers' Sotyktu and Amgen's Otezla, plus injectables including Johnson & Johnson's Tremfya, AbbVie's Skyrizi, and Novartis' Cosentyx. Takeda's pill offers a convenient daily pill alternative alongside Sotyktu and Otezla in a market dominated by injectable drugs for treating plaque psoriasis, in which red, scaly patches occur on the skin due to an overactive immune system. The company is banking on the blockbuster potential of zasocitinib to help fill a revenue gap it faces after its inflammatory bowel disease drug Entyvio loses key patents at the end of the decade. Takeda in January had said it expects zasocitinib, if approved, to generate peak annual sales in the range of $3 billion to $6 billion. The drugmaker acquired zasocitinib from drug developer Nimbus Therapeutics in 2022 in a deal worth up to $6 billion. Nimbus had identified the compound with the help of AI, a trend picking up pace in the pharmaceutical industry as companies seek to accelerate development of medicines. The drug was generally well tolerated and outperformed placebo and Amgen's Otezla, with treatment responses strengthening through week 24. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Leroy Leo)

AcquisitionDrug ApprovalClinical Result

19 Dec 2025

·www.biospace.com

Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data

iStock, Veronique D With zasocitinib, Takeda is looking to challenge Bristol Myers Squibb’s kinase inhibitor Sotyktu, for which the Japanese pharma is running a head-to-head study in plaque psoriasis. Takeda expects to zasocitinib’s FDA approval next year. Takeda’s oral drug candidate zasocitinib significantly eased disease severity in two late-stage plaque psoriasis studies, setting the Japanese pharma up to challenge Bristol Myers Squibb in this indication. “The oral psoriasis segment is projected to exceed $5B by 2030,” analysts at Jefferies told investors in a Thursday note, explaining that patients are partial to pills over injectables. In this area, zasocitinib’s “strong efficacy and safety pro regulatory approval,” the firm continued. Takeda expects to new drug application for zasocitinib at the start of its 2026 fiscal year, which begins in April. Takeda acquired zasocitinib from Nimbus Therapeutics for $4 billion at the end of 2022, outcompeting “almost every biopharmaceutical company” to get it, according to Andy Plump, Takeda’s head of research and development. Across the two Phase III LATITUDE studies, Takeda enrolled more than 1,800 adults with moderate to severe plaque psoriasis. Both studies compared zasocitinib with placebo and Amgen’s Otezla. Data were sparse in the pharma’s Thursday release , in which it noted that “on average about 30 percent” of treated patients achieved completely clear skin, or a score of 100 on the Psoriasis Area and Severity Index (PASI). Meanwhile, “more than half” of patients hit PASI 90, indicating clear or almost clear skin. Despite the lack of details, Jefferies said that zasocitinib “demonstrated best-in-class Ph3 results,” which in turn point to its “potential to redefine the oral psoriasis market.” Zasocitinib is an AI-designed molecule, something which trial organizers said helped make its targeting “ 1.7 million times ” more selective than other drugs for psoriasis. After a reshuffle of pipeline priorities and dropping its entire cell therapy program this fall, Takeda re-upped a pact with AI-discovery firm Nabla Bio to refill its early pipeline. With zasocitinib, Takeda is stepping up to Bristol Myers Squibb and its oral tyrosine kinase inhibitor Sotyktu, which was approved in September 2022 for plaque psoriasis. Sotyktu made $246 million worldwide for BMS last year, a 45% year-on-year increase. Takeda is running a Phase III head-to-head study that compares zasocitinib against Sotyktu in moderate to severe plaque psoriasis. The trial is expected to be completed in July next year. Aside from Sotyktu, Takeda’s zasocitinib will also be going up against Johnson & Johnson’s icotrokinra, which in March this year hit a 50% PASI 90 response. Truist in its note said that zasocitinib appears “comparable” to icotrokinra, however noting that J&J’s molecule “has first mover advantage with PDUFA expected sometime in 2026.”

Phase 3AcquisitionClinical ResultDrug ApprovalCell Therapy

100 Deals associated with Zasocitinib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthritis, Psoriatic	Phase 3	United States	Takeda Pharmaceutical Co., Ltd.	03 Mar 2025
Arthritis, Psoriatic	Phase 3	Belgium	Takeda Pharmaceutical Co., Ltd.	03 Mar 2025
Arthritis, Psoriatic	Phase 3	Bulgaria	Takeda Pharmaceutical Co., Ltd.	03 Mar 2025
Arthritis, Psoriatic	Phase 3	Chile	Takeda Pharmaceutical Co., Ltd.	03 Mar 2025
Arthritis, Psoriatic	Phase 3	Colombia	Takeda Pharmaceutical Co., Ltd.	03 Mar 2025
Arthritis, Psoriatic	Phase 3	Croatia	Takeda Pharmaceutical Co., Ltd.	03 Mar 2025
Arthritis, Psoriatic	Phase 3	Czechia	Takeda Pharmaceutical Co., Ltd.	03 Mar 2025
Arthritis, Psoriatic	Phase 3	Estonia	Takeda Pharmaceutical Co., Ltd.	03 Mar 2025
Arthritis, Psoriatic	Phase 3	Germany	Takeda Pharmaceutical Co., Ltd.	03 Mar 2025
Arthritis, Psoriatic	Phase 3	Hungary	Takeda Pharmaceutical Co., Ltd.	03 Mar 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05153148 (EULAR2025)	Phase 2	Arthritis, Psoriatic	290	ZASOCITINIB 15mg	fdifjwrsjv(rgoarrrchl) = hxznmsozyo toomwzkdhn (anullpewgu )	Positive	11 Jun 2025
				ZASOCITINIB 30mg	fdifjwrsjv(rgoarrrchl) = ihscboubso toomwzkdhn (anullpewgu )
NCT05153148 (EULAR2025)	Phase 2	Arthritis, Psoriatic	290	Zasocitinib 15 mg	yybbyezcmv(awhlvadbxl) = Among ACR20 responders, zasocitinib-treated patients generally exhibited dose-dependent reductions from baseline in IL-6, VEGF-A, CCL8 and TWEAK at both Weeks 4 and 12. Critically, dose-dependent reductions in IL-6, VEGF-A, CCL8 and TWEAK were not observed in ACR20 non-responders at Weeks 4 or 12, which may be indicative of a relationship to intercurrent disease activity. Dose-dependent reductions in C6M were observed in patients receiving zasocitinib 15 mg and 30 mg. qgstwknuuz (yluecztlqs )	Positive	11 Jun 2025
				Zasocitinib 30 mg
NCT05153148 (ACR2024)	Phase 2	Arthritis, Psoriatic	290	Zasocitinib 15 mg	zywupbubwf(zbbdxervjd) = ypxmdmdepv clohhlkdzc (ugiuppolza )	Positive	10 Nov 2024
				Zasocitinib 30 mg	zywupbubwf(zbbdxervjd) = kpkgphglqt clohhlkdzc (ugiuppolza )
NCT05153148 (ACR2024)	Phase 2	Arthritis, Psoriatic	290	Placebo	ostgwnuhpx(dbhxjuencq) = vsbcsqkyap kwnprfbtkp (fhhhlxyjxg )	Positive	10 Nov 2024
				Zasocitinib 5mg	bhswsrogkk(lphucbtica) = vstcvvahyx ebfakxhcau (opqlgtzysx )
NCT05153148 (ACR2024)	Phase 2	Arthritis, Psoriatic	290	Zasocitinib 15 mg	vnqsqgdfxl(evoxbulvvi) = pvvnreadzy ltjqyhcjqa (dsdbkgrkql )	Positive	10 Nov 2024
				Zasocitinib 30 mg	vnqsqgdfxl(evoxbulvvi) = xtgcifuiiw ltjqyhcjqa (dsdbkgrkql ) View more
NCT05153148 (ACR2024)	Phase 2	Arthritis, Psoriatic	290	Zasocitinib 15 mg	-	Positive	10 Nov 2024
				Zasocitinib 30 mg
NCT04999839 (Pubmed \| JAMA Dermatol) Manual	Phase 2	Plaque psoriasis	259	Zasocitinib 2 mg	xegphweyfa(oxyhqaszin) = brnbyoikxs imtrfbbbiy (uryhboiruk )	Positive	01 Oct 2024
				Zasocitinib 5 mg	xegphweyfa(oxyhqaszin) = bbobwfxjrk imtrfbbbiy (uryhboiruk )
NCT05153148 (CTgov)	Phase 2	Arthritis, Psoriatic	305	Placebo (Placebo)	obcsxhzaun = vgdonszgce hacdjwubbw (ltvjoseydf, ttzjjmjbff - utzdlatkaq) View more	-	31 May 2024
				NDI-034858 (NDI-034858 Low Dose)	obcsxhzaun = uawplnhbcs hacdjwubbw (ltvjoseydf, vgjjfnakic - odpeyocbfb) View more
NCT05153148 (ACR2023) Manual	Phase 2	Arthritis, Psoriatic	290	TAK-279 5TAK-279 5 mg	rxibllhdta(rdyalrbzga) = gvngdcloso mflyzdybrl (wmtcuhznxf ) View more	Positive	24 Oct 2023
				TAK-279 15 mg	rxibllhdta(rdyalrbzga) = ftmvkknghl mflyzdybrl (wmtcuhznxf ) View more
NCT04999839 (EADV2023)	Phase 2	Psoriasis	259	TAK-279 2 mg	oyfxntbtrw(dbanvswqph) = wmbmwelhei usjhrfhhkt (eiekwpiobm ) View more	Positive	11 Oct 2023
				TAK-279 5 mg	oyfxntbtrw(dbanvswqph) = ujoukcsdro usjhrfhhkt (eiekwpiobm ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Zasocitinib

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation